Pembrolizumab - Revision history

Aidan at 15:35, 2 October 2025

2025-10-02T15:35:19Z

← Older revision		Revision as of 15:35, 2 October 2025
Line 9:		Line 9:
	=== Adverse Effects ===		=== Adverse Effects ===

			* Common adverse effects include fatigue, rash, myalgias, nausea
	* Immune-related adverse events are common		* Immune-related adverse events are common, including rash

	==== Immune-Mediated Pneumonitis ====		==== Immune-Mediated Pneumonitis ====

Aidan at 13:48, 25 July 2023

2023-07-25T13:48:43Z

← Older revision		Revision as of 13:48, 25 July 2023
Line 18:		Line 18:
	* Most cases are mild to moderate, though there has been at least one death		* Most cases are mild to moderate, though there has been at least one death
	* Pattern on radiography is of [[ILD]] (mostly [[organizing pneumonia]], but occasionally [[NSIP]]), [[hypersensitivity pneumonitis]], or ground-glass opacities[[CiteRef::delaunay2019ma]]		* Pattern on radiography is of [[ILD]] (mostly [[organizing pneumonia]], but occasionally [[NSIP]]), [[hypersensitivity pneumonitis]], or ground-glass opacities[[CiteRef::delaunay2019ma]]
	* May be managed with prednisone		* May be managed with [[prednisone]]

			=== Infections ===

			* Not particularly immunosuppressive
			* Severe infections include mainly bacterial infections ([[pneumonia]], [[genitourinary infection]], [[SSTI]], and [[bacteremia]])
			* Possibly occasional viral infections ([[enterovirus]] and [[rhinovirus]]), rare fungal infections

	[[Category:Immune checkpoint inhibitors]]		[[Category:Immune checkpoint inhibitors]]

Aidan at 13:46, 25 July 2023

2023-07-25T13:46:47Z

← Older revision		Revision as of 13:46, 25 July 2023
Line 19:		Line 19:
	* Pattern on radiography is of [[ILD]] (mostly [[organizing pneumonia]], but occasionally [[NSIP]]), [[hypersensitivity pneumonitis]], or ground-glass opacities[[CiteRef::delaunay2019ma]]		* Pattern on radiography is of [[ILD]] (mostly [[organizing pneumonia]], but occasionally [[NSIP]]), [[hypersensitivity pneumonitis]], or ground-glass opacities[[CiteRef::delaunay2019ma]]
	* May be managed with prednisone		* May be managed with prednisone
			[[Category:Immune checkpoint inhibitors]]

	[[Category:Medications]]
	[[Category:Oncology]]

Aidan: Created page with "== Background == * Monoclonal antibody to programmed cell death 1 (PD-1) * Increases anti-tumour T-cell response by blocking interaction between PD-1 on T-cells and PD-L1 on..."

2021-05-24T18:07:45Z

Created page with "== Background == * Monoclonal antibody to programmed cell death 1 (PD-1) * Increases anti-tumour T-cell response by blocking interaction between PD-1 on T-cells and PD-L1 on..."

New page

== Background ==

* Monoclonal antibody to programmed cell death 1 (PD-1)
* Increases anti-tumour T-cell response by blocking interaction between PD-1 on T-cells and PD-L1 on cancer cells
* Indications include [[melanoma]] and [[non-small cell lung cancer]]

== Safety ==

=== Adverse Effects ===

* Immune-related adverse events are common

==== Immune-Mediated Pneumonitis ====

* Pneumonitis in a life-threatening side effect occuring in 1-5% of treated patients[[CiteRef::leroy2017pe]]
* Slightly more frequent in patients with known [[asthma]] or [[COPD]], or who have received chest radiation
* Median time to onset is 2.8 months
* Most cases are mild to moderate, though there has been at least one death
* Pattern on radiography is of [[ILD]] (mostly [[organizing pneumonia]], but occasionally [[NSIP]]), [[hypersensitivity pneumonitis]], or ground-glass opacities[[CiteRef::delaunay2019ma]]
* May be managed with prednisone

[[Category:Medications]]
[[Category:Oncology]]